IDH1-VAC (IDH1 R132H Peptide Vaccine)
IDH1-vac
not stated in source · Single arm
newly diagnosed IDH1 R132H astrocytoma
vaccine-induced immune response: 93.3%, 28 of 30 evaluable
3-year PFS rate: 63%
NOA-16 · NCT02454634
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
IDH-mutant glioma
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
7 arms have a reported figure.
IDH1-vac
not stated in source · Single arm
newly diagnosed IDH1 R132H astrocytoma
vaccine-induced immune response: 93.3%, 28 of 30 evaluable
3-year PFS rate: 63%
NOA-16 · NCT02454634
Ivosidenib, non-enhancing glioma
Phase 1 doses · Single arm
recurrent non-enhancing IDH1-mutant glioma
median PFS: 13.6 months, 95% CI 9.2 to 33.2
Ivosidenib Phase 1 (glioma) · NCT02073994
Olutasidenib 150 mg BID
150 mg · Single arm
relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable)
objective response rate: 8%, 2 of 25
disease control rate: 48%, 12 of 25
Olutasidenib Phase 1/2 (glioma cohort) · NCT03684811
Safusidenib 250 mg BID
250 mg · Single arm
IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)
confirmed objective response rate: 51.9%, median follow-up 38.8 months
36-month PFS rate: 79.1%, median follow-up 38.8 months
J201 Phase 2 · NCT04458272
Vorasidenib 40 mg daily
40 mg · ITT
grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)
Comparator: placebo
PFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysis
time to next intervention hazard ratio: 0.26 HR, primary analysis
median time to next intervention, placebo: 17.8 months, primary analysis
median PFS, vorasidenib: 27.7 months, NEJM 2023
median PFS, placebo: 11.1 months, NEJM 2023
median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminary
objective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary
INDIGO · NCT04164901
Vorasidenib, non-enhancing glioma
Phase 1 doses · Single arm
recurrent non-enhancing IDH-mutant glioma (n = 22)
objective response rate: 18%, Phase 1
median PFS: 36.8 months, Phase 1
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.